Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,636.36
(
2.00%
)
US TECH 100
23,770.40
(
2.10%
)
Dow Jones
46,585.22
(
2.21%
)
Brent Oil
95.75
(
-11.45%
)
Bitcoin
70,901.38
(
4.52%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 2684

Wednesday, 06/30/2004 3:23:04 PM

Wednesday, June 30, 2004 3:23:04 PM

Post# of 257269
>> Just curious why you think this would present an obstacle.... <<

If Levitt et al think the Squalamine rights in cancer are worth a bundle, but the other party to the negotiation thinks they aren’t, you can have a “valuation gap” even if both sides agree about what Squalamine is worth in AMD. I’m not implying that this is what happened in the discussions with Merck, but it is one possible scenario.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today